Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Adjuvant Vaccines Could Have Helped To Prevent H1N1 Shortfall, Industry Tells Congress

This article was originally published in The Pink Sheet Daily

Executive Summary

FDA has yet to approve adjuvanted influenza vaccines when they have been in use in Europe since 1997.

You may also be interested in...



Adjuvants Need Approval Pathway Separate From Vaccines, Industry Tells FDA

Industry is calling on FDA to write separate rules for assessing adjuvants. This would encourage innovation in immunotherapies, the Biotechnology Industry Organization and Pharmaceutical Research and Manufacturers of America contend.

Adjuvants Need Approval Pathway Separate From Vaccines, Industry Tells FDA

Industry is calling on FDA to write separate rules for assessing adjuvants. This would encourage innovation in immunotherapies, the Biotechnology Industry Organization and Pharmaceutical Research and Manufacturers of America contend.

Adjuvanted Flu Vaccines Get Booster: House Report Presses FDA On Approval

House appropriators are pressing FDA to license adjuvanted seasonal influenza vaccines that have a proven safety record.

Related Content

Topics

UsernamePublicRestriction

Register

PS068763

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel